← back to search

David I. Marks

University Hospitals Bristol NHS Foundation Trust · GB
Area of research
Hematology · Public Health, Environmental and Occupational Health
Research interest
Research interests include Acute Lymphoblastic Leukemia research, Hematopoietic Stem Cell Transplantation, Chronic Myeloid Leukemia Treatments, and Acute Myeloid Leukemia Research.
h-index
75
citations
20,964
works
362
NIH funding
primary concept
Medicine
email

Recent publications

Real-world outcomes of infections following tisagenlecleucel in patients with B-cell ALL: a CIBMTR analysis
Blood Advances 2025cited by 5position: middledoi
Writing a Medical Memoir: Lessons From a Long, Steep Road.
2025cited by 0position: contributordoi
Management of ALL in adults: 2024 ELN recommendations from a European expert panel
Blood 2024cited by 104position: middledoi
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With <i>NPM1</i> and <i>FLT3</i> Mutations
Journal of Clinical Oncology 2024cited by 39position: middledoi
Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors
JAMA Oncology 2022cited by 76position: middledoi
Molecular classification improves risk assessment in adult <i>BCR-ABL1–</i>negative B-ALL
Blood 2021cited by 116position: middledoi
Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia
Blood Advances 2021cited by 76position: middledoi
Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes
Transplantation and Cellular Therapy 2021cited by 31position: middledoi
Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation
Transplantation and Cellular Therapy 2021cited by 24position: middledoi
Return to Work Among Young Adult Survivors of Allogeneic Hematopoietic Cell Transplantation in the United States
Transplantation and Cellular Therapy 2021cited by 24position: middledoi
Survival following allogeneic transplant in patients with myelofibrosis
Blood Advances 2020cited by 96position: middledoi
Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome–positive relapsed/refractory acute lymphoblastic leukemia
Cancer 2020cited by 75position: middledoi
Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden
Blood Cancer Journal 2020cited by 67position: middledoi
Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia
Blood Advances 2020cited by 51position: middledoi
Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT
Journal of Clinical Oncology 2020cited by 49position: middledoi
Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report
Blood Advances 2020cited by 34position: middledoi
Bortezomib-Based Induction Is Associated with Superior Outcomes in Light Chain Amyloidosis Patients Treated with Autologous Hematopoietic Cell Transplantation Regardless of Plasma Cell Burden
Transplantation and Cellular Therapy 2020cited by 17position: middledoi
At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial
British Journal of Haematology 2020cited by 17position: middledoi
A Phase 3 Randomized Study of Remestemcel-L versus Placebo Added to Second-Line Therapy in Patients with Steroid-Refractory Acute Graft-versus-Host Disease
Biology of Blood and Marrow Transplantation 2019cited by 197position: middledoi
The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia
Blood Advances 2019cited by 99position: middledoi
Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia
Biology of Blood and Marrow Transplantation 2019cited by 76position: firstdoi
Comprehensive Prognostication in Critically Ill Pediatric Hematopoietic Cell Transplant Patients: Results from Merging the Center for International Blood and Marrow Transplant Research (CIBMTR) and Virtual Pediatric Systems (VPS) Registries
Biology of Blood and Marrow Transplantation 2019cited by 48position: middledoi
Mesenchymal stromal cells for acute graft‐versus‐host disease: response at 1 week predicts probability of survival
British Journal of Haematology 2019cited by 40position: middledoi
Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research
Haematologica 2019cited by 37position: middledoi
Alternative donor transplantation for acute myeloid leukemia in patients aged ≥50 years: young HLA-matched unrelated or haploidentical donor?
Haematologica 2019cited by 31position: middledoi
Virus detection in the cerebrospinal fluid of hematopoietic stem cell transplant recipients is associated with poor patient outcomes: a CIBMTR contemporary longitudinal study
Bone Marrow Transplantation 2019cited by 26position: middledoi
Association of Antiepileptic Medications with Outcomes after Allogeneic Hematopoietic Cell Transplantation with Busulfan/Cyclophosphamide Conditioning
Biology of Blood and Marrow Transplantation 2019cited by 20position: middledoi
Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation
Biology of Blood and Marrow Transplantation 2019cited by 19position: middledoi
GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia
Blood Advances 2019cited by 19position: middledoi
Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
Bone Marrow Transplantation 2018cited by 155position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Nicola Gökbuget · Frankfurt Cancer Institute8 papers (2018–2024)Bipin N. Savani · Medical College of Wisconsin8 papers (2013–2019)Wendy Stock · Leukemia Research Foundation7 papers (2018–2020)Matthias Stelljes · The Ohio State University7 papers (2018–2020)Hillard M. Lazarus · Case Western Reserve University7 papers (2013–2020) · 7 papers (2018–2020) · 6 papers (2018–2020)Daniel J. DeAngelo · Harvard University6 papers (2018–2020)Anjali S. Advani · Cleveland Clinic6 papers (2018–2020)Hagop M. Kantarjian · The University of Texas MD Anderson Cancer Center6 papers (2018–2020)Parameswaran Hari · Medical College of Wisconsin5 papers (2013–2020)Wael Saber · Benha University5 papers (2013–2016)Michaela Liedtke · Stanford University5 papers (2018–2020)Robert Peter Gale · Chongqing Cancer Hospital5 papers (2013–2019)Kwang Woo Ahn · Medical College of Wisconsin4 papers (2013–2017)Susan O’Brien · University of California, Irvine4 papers (2018–2020)Elias Jabbour · The University of Texas MD Anderson Cancer Center4 papers (2018–2020)Baldeep Wirk · Virginia Commonwealth University4 papers (2013–2017)Ryan D. Cassaday · University of Washington4 papers (2018–2020)Rammurti T. Kamble · Webster University4 papers (2013–2020)